Patient ID: 20041410

Gender: M

Date Of Note: 07/12/2022 09:14

MOSAIQ Progress Notes

BY: Strouthos,Iosif Consultation on 05/12/22 GESY Patient / Referral from Dr. O. Tsavaris Diagnosis: Prostate Ca ID: 2001 Localization: Bilobar Histology: Invasive adenocarcinoma of the prostate Classification: cT3a cN1 cM1 (metastatic disease) Metastases: LYM (Pelvic, retroperitoneal, supradiaphragmatic LNs), OSS (Th3, Th12, Rt 7th rib, L5) PSA: 238 ng/ml Secondary Diagnoses: None Previous treatment/Course of disease: 2001 Biopsy: confirmation of malignancy, Gleason score 5 (2+3) (no report submitted) 2001 2x Hypethermia as well as diverse alternative treatments 2018-21 Initiation of anti-androgen, Bicalutamide (initially 50 mg then 150 mg) 2021 Gradual PSA despite Bicalutamide 05/22 Ga68-PSMA PET/CT (Wiesbaden, Germany): highly PSMA expressing prostatic malignancy with SV invasion, and ECE with at least contact to the anterior rectal wall. Highly PSMA positive pelvic and retroperitoneal LNs, supradiaphragmatic LNs, and multiple bone lesions (Th3, Th12, 7th rib, L5) 05/22 MRI Pelvis: Prostate volume 43cc. PI-RADS V lesion within the posterior PZ extending just above the apex of the prostate. 11/22 ADT initiation with Goserelin 10.8 mg (GOC) Family history: None Treatment concept: Currently oligometastatic setting RTx of the primary plus SABR of the T3 lesion In parallel ADT +/- ARAT Clinical examination: ECOG 1 VAS 0 Medication: Tumorboard: UroTB Pending issues: 1.Planning CT 2.PSMA-PET/CT Follow-up: MO